RE:RE:RE:ONCY pelareorep + PARP inhibitors = enhanced sensitization Precision cancer medicine uses targeted drugs and immunotherapies engineered to directly attack the cancer cells with specific abnormalities, leaving normal cells largely unharmed.
Precision cancer medicines can be used both instead of and in addition to chemotherapy to improve treatment outcomes.
Precision cancer medicines that target and inhibit this enzyme may contribute to cancer cell death and increased sensitivity to chemotherapy and are called PARP inhibitors. By blocking this enzyme, DNA inside the cancerous cells is less likely to be repaired, leading to cell death and possibly a slow-down or stoppage of tumor growth.
By precisely combining PARP inhibitors with ICIs, chemotherapy and ONCY's pelareorep, treatment outcomes can be significantly improved over current therapies. ONCY has already demonstrated that the I/O combination of pelareorep + ICIs + chemotherapy is effective in the treatment of multiple cancers.